Background: The relationship between metformin use and the risk of prostate cancer is still inconclusive. Therefore, we performed a systematic review and meta-analysis of all eligible cohort studies to evaluate a potential association of metformin use with prostate cancer risk. Methods: A comprehensive literature search was performed in PubMed and Web of Science databases through July 2018. A DerSimonian and Laird random-effects model was applied to calculate the pooled relative risk (RR) and its 95% confidence interval (CI). Results: Eighteen cohort or nested case-control studies were included in this study with a total of 52,328 cases. In a random-effect pooled analysis, metformin use was not significantly associated with the risk of prostate cancer (RR 0.97, 95% CI 0.80-1.16, P = .711). Statistically significant heterogeneity was identified among included studies (P < .001, I-2 = 98.1%). Sensitivity analysis indicated that no single study dominated the pooled RR. Conclusion: The present large meta-analysis of cohort studies did not find an association between metformin use and prostate cancer risk.
第一作者单位：[1]Department of Urology, China-Japan Friendship Hospital, Beijing, China.[*1]Department of Urology, China-Japan Friendship Hospital, NO.2, East Yinghua Street, Beijing 100029, China
通讯作者：
通讯机构：[1]Department of Urology, China-Japan Friendship Hospital, Beijing, China.[*1]Department of Urology, China-Japan Friendship Hospital, NO.2, East Yinghua Street, Beijing 100029, China
推荐引用方式(GB/T 7714)：
Zhaohan Feng,Xiaofeng Zhou,Naibo Liu,et al.Metformin use and prostate cancer risk A meta-analysis of cohort studies[J].MEDICINE.2019,98(12):doi:10.1097/MD.0000000000014955.
APA：
Zhaohan Feng,Xiaofeng Zhou,Naibo Liu,Jianfeng Wang,Xing Chen&Xin Xu.(2019).Metformin use and prostate cancer risk A meta-analysis of cohort studies.MEDICINE,98,(12)
MLA：
Zhaohan Feng,et al."Metformin use and prostate cancer risk A meta-analysis of cohort studies".MEDICINE 98..12(2019)
